Arbutus Biopharma Corp

ABUS • Biotechnology

$5.15

▲ +0.03 (+0.59%)

Current price

EarningsLatest report: Jun 30, 2026

WEAK PROFILEWeakConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.

Market Cap

$1.02B

Growth

-7.3%

Cash Flow

0/5

Trend

Negative

Evidence

Manageable debt level · 0.05Healthy liquidity · 15.73Negative growth trendWeak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:10 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$5.15

Change0.59%

Shares Out197.47M

Market Cap$1.02B

Enterprise Value$924.86M

52W Range3.31 - 5.38

Beta0.60

P/E6.64

P/S5.60

P/B3.93

P/FCF-41.30

EV/Sales5.09

Price$5.15

Change0.59%

Shares Out197.47M

Market Cap$1.02B

Enterprise Value$924.86M

52W Range3.31 - 5.38

Beta0.60

P/E6.64

P/S5.60

P/B3.93

P/FCF-41.30

EV/Sales5.09

EV/EBITDA6.22

EV/FCF-37.56

Earnings Yield15.05%

FCF Yield-2.42%

Dividend Yield0.00%

Gross Margin97.42%

Oper. Margin-192.08%

Profit Margin-2.38%

Debt/Eq0.05

Current Ratio15.73

Quick Ratio15.73

Revenue 5Y-7.29%

Target$8.50

Target Upside65.05%

Target Median$8.50

Target Range8.50 - 8.50

Volume1.38M

Avg Volume1.93M

EPS Surprise0.90

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

76/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

20/100

Why this score▼

Manageable debt level · 0.05Healthy liquidity · 15.73Negative growth trendWeak profitability

Analyst view

Analyst sentiment and price target

ABUS

Analyst sentiment

Based on 10 analyst votes · 2026-09-05

90/100

Bullish

Hold

Bearish

Price Target

2026-08-14

Low

$8.50

Mean

$8.50

Median

$8.50

High

$8.50

Company Overview

IPO: 7/26/2007

Industry: Biotechnology

P/B i: 3.93

Debt / Equity i: 0.05

Operating Margin: -192.08%

Net Margin: -237.88%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.05

Current Ratio: 15.73

Quick Ratio: 15.73

Status: Good

Insider Transactions

Recent executive and insider activity

Beardsley Robert A

Transaction: 06/08/2026

BUY

Change

+78,800

Price

$4.24

Filing

06/10/2026

Type

BUY

Sawhney Roger

Transaction: 06/08/2026

BUY

Change

+78,800

Price

$4.24

Filing

06/10/2026

Type

BUY

Androski Lindsay

Transaction: 02/02/2026

BUY

Change

+28,000

Price

Not reported

Filing

02/02/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Beardsley Robert A	BUY	+78,800	$4.24	06/08/2026	06/10/2026
Sawhney Roger	BUY	+78,800	$4.24	06/08/2026	06/10/2026
Androski Lindsay	BUY	+28,000	Not reported	02/02/2026	02/02/2026
Androski Lindsay	BUY	+71,700	$4.39	02/02/2026	02/02/2026
Nguyen Tuan	BUY	+73,500	Not reported	02/02/2026	02/02/2026
Nguyen Tuan	BUY	+188,400	$4.39	02/02/2026	02/02/2026
Sawhney Roger	OTHER	0	Not reported	08/04/2025	08/06/2025
Sawhney Roger	BUY	+157,600	$3.34	08/04/2025	08/06/2025
Nguyen Tuan	BUY	+750,000	$3.49	03/31/2025	04/01/2025
Nguyen Tuan	BUY	+750,000	$3.50	03/31/2025	03/31/2025
Nguyen Tuan	OTHER	0	Not reported	03/28/2025	03/31/2025
Androski Lindsay	BUY	+310,422	$3.20	03/18/2025	03/20/2025
Beardsley Robert A	BUY	+157,600	$3.20	03/18/2025	03/20/2025
Hasija Anuj	BUY	+157,600	$3.20	03/18/2025	03/20/2025
Gline Matthew	OTHER	0	Not reported	02/24/2025	03/06/2025
Androski Lindsay	OTHER	0	Not reported	02/24/2025	03/06/2025
Beardsley Robert A	OTHER	0	Not reported	02/24/2025	03/06/2025
Bishop Joseph E	OTHER	0	Not reported	02/24/2025	03/06/2025
Hasija Anuj	OTHER	0	Not reported	02/24/2025	03/06/2025
Sims Karen	BUY	+49,300	Not reported	02/14/2025	02/19/2025

About the Company

Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Source - link

Peers

BCAX EYPT GHRS KURA NBTX PROK SEPN SPRY SVRA TNGX

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Connor Clark & Lunn Investment Management Ltd. Buys Shares of 130,023 Arbutus Biopharma Corporation $ABUS

Connor Clark and Lunn Investment Management Ltd. purchased a new position in shares of Arbutus Biopharma Corporation (NASDAQ: ABUS) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 130,023 shares of the biopharmaceutical company's stock, valued at approximately $624,000. Connor Clark and Lunn Investment Management Ltd.

Defense World

Bank of America Corp DE Has $7.58 Million Stock Position in Arbutus Biopharma Corporation $ABUS

Bank of America Corp DE lowered its stake in Arbutus Biopharma Corporation (NASDAQ: ABUS) by 8.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,683,628 shares of the biopharmaceutical company's stock after selling 149,076 shares during the quarter. Bank of

Defense World

Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

WARMINSTER, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the commencement of a modified “Dutch Auction” tender offer to purchase for cancellation up to US$230 million in value of its common shares (the “Shares”) at a price of not less than US$5.00 and not more than US $5.75 per Share, less any applicable withholding taxes and without interest, on the terms and subject to the conditions described in the offer to purchase and accompanying issuer bid circular, dated August 24, 2026 (the “Offer to Purchase and Bid Circular”), the Letter of Transmittal (the “Letter of Transmittal”) and Notice of Guaranteed Delivery (the “Notice of Guaranteed Delivery”) (which together, as they may be amended and supplemented from time to time, constitute the “Offer”).

GlobeNewsWire

Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced plans to commence a modified “Dutch Auction” tender offer (the “Offer”) to repurchase up to US$230 million of its common shares at a purchase price of not less than US$5.00 per share and not more than US$5.75 per share, in cash, less any applicable withholding taxes and without interest. The Offer is expected to commence on or about August 24, 2026 and, unless extended or terminated by the Company, expire on or about September 29, 2026. The Offer is expected to be funded through the Company's cash on hand.

GlobeNewsWire

Head-To-Head Comparison: YD Bio (NASDAQ:YDES) versus Arbutus Biopharma (NASDAQ:ABUS)

Arbutus Biopharma (NASDAQ: ABUS - Get Free Report) and YD Bio (NASDAQ: YDES - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations and valuation. Profitability This table compares Arbutus Biopharma and

Defense World

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-13	-0.03	0.87	0.9
2026-03-23	-0.03505	-0.01	0.02505
2025-11-13	-0.056	-0.04	0.016
2025-08-06	-0.02	0.01	0.03
2025-05-14	-0.09	-0.13	-0.04
2025-03-27	-0.08	-0.07	0.01
2024-11-06	-0.1	-0.1	0
2024-08-01	-0.1	-0.11	-0.01
2024-05-02	-0.1	-0.1	0
2024-02-29	-0.12	-0.12	0
2023-11-07	-0.12	-0.12	0
2023-08-03	-0.12	-0.1	0.02